Potential conflicts of interest are increasingly common in medicine
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/5d158dab-4479-4aaf-a890-0321bb2dfb70/650x450-Cleveland-Clinic-Cancer_jpg)
650×450-Cleveland-Clinic-Cancer
By Mikkael Sekeres, MD, MS
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
My mother-in-law was in need of a new hip. She met with the orthopedist who would perform her surgery, and the two quickly bonded.
“Now, I have to tell you that the artificial hip I’m going to use is one that I had a hand in inventing, and although I will receive no royalties for implanting this hip in you, I do have a conflict of interest, and want to make sure you’re OK with that,” he said.
I sit on our institution’s conflict of interest committee. There are a number of different types of potential conflicts that can arise. Though they don’t constitute the majority of doctor-patient interactions, scenarios where a doctor invents a technology or develops a drug and receives payments every time that technology or drug is used are becoming increasingly common.
Video content: This video is available to watch online.
View video online (https://www.youtube.com/embed/zZivfsLvPzg?feature=oembed)
Read the full New York Times column by Dr. Sekeres,
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients